Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ABIO - nice action yesterday and pre-market today. I wonder what is driving this again? There was no news yesterday...or today that I can tell. INSIDER BUYING maybe?? Go ABIO!!
What is your proof there is a short squeeze - because I read about short squeezes from trips up - but I have only seen 2 short squeezes and one was suspended after 2 weeks.
There is absolutely no evidence of a short squeeze.
IG
There is no share offering yet. We would have news of that combined with offering. Price just retracted.
I called a $10/share offering when this was at $14. FWIW
ABIO buy 10.74
http://arcabio.com/
normal chart
log chart
This one I expect an offering announcement soon as you know
Wrong board sorry
Up 3% and climbing! Rally underway
My best pick for today is X US STEEL.
Yesterday went as high as 20.00 sold that one, now DFF$ on the move to 7-8 today.
and is getting a lot cheaper. wasn't this just 23.00?
Well for one, I think it's too soon for an offering. This just reverse split about a month or so ago. It held pretty steady after the reverse split unlike some that crash and burn immediately so that was encouraging. I was at loss (my average after split....13.95....yeah I bought high at
.85 awhile back before RS.) So anyway....just sat on it and didn't average down. Waited for trial results....which you see what happened with that:) Anyway, a public offering basically brings the price down but often it's only temporary. 1 to 2 weeks. If that. If there is enough interest and people buy the offering, price should go back up if company is doing well. I will hold through any offering and maybe buy more. I personally don't think they would have an offering until after phase 3 trials. If that were to go well then yeah...for sure we would see an offering at some point. This is all just my opinion. I'm still holding. Rats wish I caught that $20 but was at work. Put in sale orders near middle of day....right before it dropped. Sooooo..just gonna hold through consolidation. This could be really big if phase 3 trials are successful. Really big. Atrial fibrillation is no joke and if they have some groundbreaking medicine that's better than the current beta blockers and gets approved by FDA....this could be $100 stock in a few years. All my opinion! Do your own DD
Can you explain how an offering would affect those holding?
* * $ABIO Video Chart 05-02-2019 * *
Link to Video - click here to watch the technical chart video
Danger of offering AH I wouldn’t hold personally but what do I know?
Just found this one today. Looking at an entry. But not sure as it’s been sideways for most of the afternoon. Any thoughts on where this goes on this news? I saw it hit $20 early. Wow considering it was in the $1 range just a few weeks ago
This thing can’t hold any upward momentum.
Still holding here. Missed that $20 this morning rats. Might as well just hold on. I can only swing or hold.
Won’t they do an offering now? Announced AH? Forcing this to drop 50% immediately? Or no?
$16.25 nice :)
Textbook BPT$ pattern washed out all the weak, now it will run past $20 again without hesitation
lol premarket shake and bake. Love short squeezes
This will halt at some point. Going nuts!!
This has been more fun than Mary Jane.....
Got in at $11.59 yesterday, put a sell order GTC at $18.25 and just checked.... I'm out...
GLTA, I hope it goes to $40
Squeeze!!
ABIO
Damn, was going to buy PM in low 10’s but did not pull the trigger. Sure many made money on this. Probably will pull back toward open.
What happen today??
Deep Red? or Small Consi?
(((((KABOOMAGE)))))!! 2.0
$ABIO ARCA bio up 36% on "positive" bucindolol data
https://seekingalpha.com/news/3457116-arca-bio-36-percent-positive-bucindolol-data
Shake and bake!
wow. what a move today on massive volume
Surprised there wasn’t an offering. But, good day all the same. Might trade tomorrow too in a lower range.
One seriously undervalued stock.
https://alphastocknews.com/arca-biopharma-abio-stock-why-you-may-want-to-consider-jumping-in/185/
* * $ABIO Video Chart 05-01-2019 * *
Link to Video - click here to watch the technical chart video
Exactly, there is that very common risk with these biopharmas.
I was tempted to buy in again, but will hold back. Plus ABIO isn't in FDA phase III clinical trials yet.
May see huge upside gapper @ opening bell.
Watch out for an offering. Not sure i would hold this overnight
Followers
|
104
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2418
|
Created
|
12/11/06
|
Type
|
Free
|
Moderators |
***These patients experienced a 74% (p = 0.0003) reduction in risk of AF versus no detectable reduction in patients who had alternative genotypes (beta1389 Gly carriers; 53% of the patients) who had received placebo. The Company believes this data supports the potential ability of Gencaro to prevent AF in patients who have the genotype the Company believes responds most favorably to Gencaro.
The Science:
GENETIC-AF Clinical Trial
GENETIC-AF is planned as a Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing Gencaro to metoprolol CR/XL for prevention of AF in patients with heart failure and reduced left ventricular ejection fraction (HFREF). ARCA plans to enroll only patients with the genetic variant of the beta-1 cardiac receptor which the Company believes responds most favorably to Gencaro. GENETIC-AF has an adaptive design, under which the Company plans to initiate it as a Phase 2B study in approximately 200 patients and then, depending on the results of an interim analysis by the trial Data Safety Monitoring Board (DSMB), expand the trial to a Phase 3 study by enrolling an estimated additional 420 patients.
Under the collaboration with Medtronic, ARCA plans to conduct a substudy that will include continuous monitoring of the cardiac rhythms of all 200 patients enrolled during the Phase 2B portion of GENETIC-AF. Each patient will have heart rhythm monitoring via a Medtronic device, either a previously implanted cardiac resynchronization or defibrillation device, or a previously or newly inserted Reveal® loop recorder. The collaboration substudy will measure AF burden, defined as a patient’s actual time in AF regardless of symptoms. For the DSMB interim analysis, AF burden and the primary endpoint of the study, time to recurrence of symptomatic AF after electrical cardioversion, or death, will be reviewed by the DSMB to determine if there is sufficient potential for a statistically significant efficacy signal to be determined for all patients enrolled in the Phase 2B/3 study.
Gencaro Data in Atrial Fibrillation
Clinical data analysis from a post-hoc review of patient forms from the from BEST trial, a Phase 3 trial in 2,708 patients with advanced heart failure, indicate that Gencaro may have a potentially enhanced and pharmacogenetically-influenced effect in reducing and preventing AF. In that trial, patients in the Gencaro arm had a reduction in the risk of new onset AF time to event compared to patients in the placebo arm of 41% (AF measured as an adverse event/serious adverse event or as detected on surveillance ECGs, time to event analysis, p = 0.0004). In a 1,040 patient DNA substudy of BEST, Gencaro exhibited potential pharmacogenetic enhancement and differentiation for AF prevention in patients with a specific genotype (beta1389 arginine homozygous (Arg/Arg) adrenergic receptor (AR); approximately 47% of the patients). These patients experienced a 74% (p = 0.0003) reduction in risk of AF versus no detectable reduction in patients who had alternative genotypes (beta1389 Gly carriers; 53% of the patients) who had received placebo. The Company believes this data supports the potential ability of Gencaro to prevent AF in patients who have the genotype the Company believes responds most favorably to Gencaro.
In prior placebo controlled trials of beta blockers in chronic HFREF, most studies comparing beta-blockers to placebo have detected a positive signal for prevention of AF, with an event rate reduction averaging approximately 27%, although AF had not been a pre-specified primary or secondary endpoint in these studies. Currently, no beta-blocker has been approved by the U.S. Food and Drug Administration for the prevention of
AF in heart failure patients.
Gencaro™ [Bucindolol Hydrochloride]
ARCA is currently developing Gencaro™ (tradename pending FDA approval) (bucindolol hydrochloride) for the prevention of atrial fibrillation and the treatment of chronic heart failure. Gencaro™ is a pharmacologically unique beta-blocker and mild vasodilator. Gencaro™ is considered part of the beta-blocker class because of its property of blocking beta-1 as well as beta-2 receptors in the heart, preventing these receptors from binding with other molecules that would otherwise activate the receptor. Because of its mild vasodilator effects, the Company believes Gencaro™ is well-tolerated in patients with advanced HF. ARCA has identified common genetic variations, or genetic markers, that it believes predict patient response to Gencaro™.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |